首页 > 市场调查报告书 > 製药

癌症分子标靶治疗学

市场调查报告书

商品编码

1838093

OX40标靶治疗药的临床试验，治疗方法，专利技术平台，市场机会(2026年)

OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 100 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

OX40标靶疗法：临床试验、治疗方法、专有技术平台和市场机会 (2026) 报告结果和亮点

首个OX40标靶疗法将于2030年获批
正在进行临床试验的OX40标靶疗法：超过10种疗法
癌症在OX40标靶疗法临床试验领域占主导地位
OX40标靶疗法临床试验洞察（按公司、国家、适应症和阶段划分）
OX40标靶疗法专有技术（依公司分法）
竞争格局

OX40/OX40L标靶疗法的需求及其重要性本报告摘要

OX40/OX40L标靶疗法作为下一代免疫调节的新靶点，正迅速受到广泛关注，尤其是在免疫介导疾病（如异位性皮肤炎、气喘和其他发炎性疾病）中。本报告概述了这个快速发展的领域，製药投资和学术兴趣正在汇聚，创造出一个充满活力的候选化合物研发管线。

随着多个候选药物进入后期临床试验阶段，以及技术创新从诊断配对扩展到联合策略，了解OX40/OX40L疗法的前景和未来方向变得前所未有的重要。本报告旨在让包括投资者、生物技术高管和临床研究人员在内的行业参与者了解这一治疗方向不断发展的潜力及其驱动因素。

本报告关于 OX40/OX40L 标靶疗法临床试验的见解

OX40/OX40L 疗法的临床发展势头强劲，多个候选药物正在研发中。尤其值得注意的是，临床试验在发炎性皮肤病治疗中显示出良好的疗效。重要的是，这些疗法展现出持久疗效和选择性免疫调节的潜力，这些特点使其有别于现有的标准治疗。在美国以外，欧洲、中国和澳洲临床活动的不断拓展显示全球对这些免疫疗法的兴趣日益浓厚。这种地理扩张标誌着全球市场对这些疗法的广泛认可，并可能为未来的监管批准铺平道路。

技术平台、合作伙伴关係和协定

本报告重点介绍的创新技术之一是 autoRx40 平台，这是一个针对 OX40 和其他相关免疫受体的专有疗法开发引擎。该技术结合了抗体工程和分子设计能力，可以快速开发双特异性和多特异性抗体。 autoRx40 的模组化设计和设计使其能够提供标靶治疗，将免疫抑制和致病性免疫细胞耗竭效应相结合。候选药物 HX035 和 HX038 是此技术在复杂自体免疫疾病治疗的应用范例。该平台反映了业界正在朝着开发可扩展且灵活的治疗引擎的方向发展，以满足不断变化的临床需求。

积极参与 OX40/OX40L 标靶疗法研发的主要公司

大型製药和生技公司也在角逐 OX40/OX40L 疗法领域。赛诺菲和安进正在完善具有重磅潜力的后期候选药物，而像 Astria Therapeutics 这样的新进入者则透过创新的工程改进展示了有希望的早期证据。像 ImageneBio 这样的公司也致力于利用成熟的抗体技术来提高安全性并最大限度地减少脱靶效应。

这些进展通常由合资企业、策略联盟和学术合作推动，它们推动创新週期并加快临床进展。随着这些疗法的进一步发展，患者反应、安全性和差异化的给药间隔可能成为市场成功的指标。

报告显示OX40/OX40L标靶疗法的未来发展

OX40/OX40L疗法正根据疾病严重程度和患者特征从单一疗法发展为联合疗法。未来，可能会出现将生物製剂与精准诊断结合以优化治疗效果的策略。具有长半衰期、低免疫原性且患者依从性良好的治疗药物正在开发中，这对现有疗法构成了巨大挑战。随着后期数据的累积和监管障碍的消除，这些疗法有可能为免疫疾病治疗树立新的标准。本文为有兴趣了解和投资未来免疫学创新浪潮的利害关係人提出了策略愿景。

First OX40 Targeted Therapy Approval By 2030
OX40 Targeted Therapies In Clinical Trials: > 10 Therapies
Cancer Dominating OX40 Targeted Therapies Clinical Trials Landscape
OX40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
OX40 Targeted Therapies Proprietary Technologies By Company
Competitive Landscape

Need For OX40/OX40L Targeted Therapies & Why This Report

OX40/OX40L targeted therapies are rapidly becoming the new target for next generation immunomodulation, especially in immune mediated disorders like atopic dermatitis, asthma, and other inflammatory conditions. This report gives an overview of this fast evolving space, where pharmaceutical investment and academia interest are merging to bring forth a vibrant pipeline of contenders.

With several candidates in late stage trials and innovation extending into combination strategies as well as diagnostic pairing, knowing the landscape and future direction of OX40/OX40L therapies has never been more important. The report is intended to educate industry players, including investors, biotech executives, and clinical researchers, on the evolving potential of this therapeutic axis and the drivers making it happen

OX40/OX40L Targeted Therapies Clinical Trials Insight Covered In Report

Clinical momentum for OX40/OX40L therapies is increasing, with multiple candidates moving through the pipeline. Particular note has been made of trials indicating promising results in inflammatory dermatological diseases, in which patients tend to have limited alternatives and relapsing disease. Significantly, these treatments are also exhibiting potential for durability of response and selective immune modulation, characteristics that set them apart from existing standards of care. Outside of the US, expanded clinical activity in Europe, China, and Australia demonstrates an expanding global interest in these immunotherapies. This geographical expansion indicates broader acceptance and future potential for regulatory paths across global markets.

Technology Platforms, Partnerships & Agreements

One of the innovations noted in this report is the autoRx40 Platform, which is a proprietary therapeutic development engine that targets OX40 and other related immune receptors. The technology combines antibody engineering and molecular design capabilities to quickly develop bispecific and multi-specific antibodies. Its modular nature and modularity of design enable autoRx40 to deliver targeted therapies that are both immune inhibiting and depleting pathogenic immune cells. The use of the technology in the treatment of complex autoimmune diseases is exemplified through candidates HX035 and HX038. The platform reflects a larger movement in the industry towards the development of scalable and flexible therapeutic engines to address the changing clinical needs.

Leading Companies Active In R&D On OX40/OX40L Targeted Therapies

Several drug making giants and biotech disruptors are making bets in the OX40/OX40L therapy arena. Sanofi and Amgen are taking late-stage candidates with blockbuster potential to the finish, while more recent entrants like Astria Therapeutics are showing promising early-stage evidence with innovative engineering improvements. Companies like ImageneBio are also targeting enhanced safety and minimized off-target effects via matured antibody technologies.

These advancements are frequently fostered by joint ventures, strategic alliances, and academic collaborations that drive innovation cycles and facilitate clinical progress. With further development of these therapies, differentiation among patient response, safety profiles, and dosing intervals will be the marker for success in the marketplace.

Report Indicating Future Development Of OX40/OX40L Targeted Therapies

OX40/OX40L therapies are progressing beyond monotherapy to combinations based on disease severity and patient profile. The future will probably witness combined strategies that bring together biologics and precision diagnostics to optimize therapeutic effects. Future contenders are being developed for longer half-life, less immunogenicity, and better patient compliance, making them strong challengers to current treatments. With late-stage data accumulated and regulatory hurdles cleared, these therapies have the potential to set new standards in immune disease therapy. This paper presents the strategic vision to stakeholders interested in learning or investing in the future wave of immunology innovation.

1. Introduction To OX40/OX40L Pathway

1.1 Background Of OX40/OX40L Pathway
1.2 Significance In Immunotherapy
1.3 OX40/OX40L As Disease Biomarkers

2. Targeting The OX40/OX40L Pathway In Therapy

2.1 OX40/OX40L Agonism
2.2 OX40/OX40L Antagonism
2.3 Targeting Approaches & Mechanisms Of Action
- 2.3.1 Antibodies
- 2.3.2 Nucleic Acids
- 2.3.3 Fusion Protein
- 2.3.4 Small Molecules
- 2.3.5 Peptides

3. Indications For OX40/OX40L Targeted Therapies

3.1 Cancer
- 3.1.1 Solid Tumors
- 3.1.2 Hematologic Malignancies
3.2 Infectious Diseases
3.3 Autoimmune & Inflammatory Diseases
3.4 Other Potential Indications

4. OX40/OX40L Targeted Combination Therapies

5. Global OX40/OX40L Targeted Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Indication
5.3 By Company

6. Global OX40/OX40L Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Preclinical
6.2 Phase 0
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III

7. OX40/OX40L Targeted Therapy Development Platforms By Company

8. Global OX40/OX40L Targeted Therapy Market Outlook

8.1 Current Market Overview
8.2 Future Prospects

9. Global OX40/OX40L Targeted Therapy Market Dynamics

9.1 Growth Drivers & Opportunities
9.2 Challenges & Strategic Solutions

10. Competitive Landscape

10.1 AbCellera Biologics
10.2 Apogee Therapeutics
10.3 Amgen
10.4 Astria Therapeutics
10.5 Bio-Thera
10.6 Elpiscience
10.7 HiFiBiO Therapeutics
10.8 Inhibrx Biosciences
10.9 ImageneBio
10.10 Kyowa Kirin
10.11 Navigator Medicines
10.12 Pfizer
10.13 Psivant Therapeutics
10.14 Sanofi
10.15 Shanghai Henlius Biotech

简介目录图表

List of Figures

Figure 1-1: OX40/OX40L Pathway
Figure 1-2: OX40 In T Cell Subset Differentiation
Figure 1-3: OX40/OX40L Signaling Pathway In Disease
Figure 2-1: OX40 Agonism - Mechanism Of Action On T Cells
Figure 2-2: OX40 Agonism - Potential For Immunotherapy Across Diseases
Figure 2-3: OX40 Antagonism - Mechanism Of Action
Figure 2-4: Types Of OX40 Targeting Antibodies
Figure 2-5: Nanobodies Targeting OX40 - A Novel Approach
Figure 2-6: Nucleic Acid-Based Therapies Targeting OX40/OX40L
Figure 2-7: Fusion Proteins Targeting OX40/OX40L - Advantages
Figure 2-8: Small Molecules Targeting OX40-OX40L - Mechanism Of Action
Figure 2-9: Bicycle Peptides Targeting OX40 - Mechanism Of Action
Figure 3-1: HexAgon-HN Phase 2/3 (NCT06295731) Study - Initiation & Completion Year
Figure 3-2: BAT-6026-001-CR Phase 1 (NCT05105971) Study - Initiation & Completion Year
Figure 3-3: HFB-301001-01 Phase 1 (NCT05229601) Study - Initiation & Completion Year
Figure 3-4: FT04CARCIK Phase 1/2 (NCT05869279) Study - Initiation & Completion Year
Figure 3-5: LY007C1101 Phase 1 (NCT06364852) Study - Initiation & Completion Year
Figure 3-6: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year
Figure 3-7: ROCKET-ASCEND Phase 3 (NCT05882877) Study - Initiation & Completion Year
Figure 3-8: ROCKET-Outpost Phase 3 (NCT06224192) Study - Initiation & Completion Year
Figure 3-9: RIVER-AD Phase 2/3 (NCT05492578) Study - Initiation & Completion Year
Figure 3-10: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year
Figure 5-1: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Phase, 2025 -2026
Figure 5-2: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Indication, 2025 - 2026
Figure 5-3: Global - OX40/OX40L Targeted Therapies In Clinical Trials By Company, 2025 - 2026
Figure 7-1: ADAPTIR Bispecific
Figure 7-2: ADAPTIR - APVO603
Figure 7-3: Genmab - HexaBody
Figure 7-4: Inhibrx - sdAb Features
Figure 7-5: Conventional vs. sdAb Structure
Figure 7-6: INBRX-106 - Features
Figure 8-1: Global OX40/OX40L Targeting Therapy Market - Future Prospects
Figure 9-1: Global OX40/OX40L Targeting Therapy Market - Drivers & Opportunities
Figure 9-2: Global OX40/OX40L Targeting Therapy Market - Challenges & Strategic Solutions

List of Tables

Table 1-1: OX40/OX40L As Prognostic Biomarker In Diseases
Table 2-1: Challenges Of OX40 Agonism - Risks & Optimizations
Table 4-1: OX40/OX40L Targeting Combination Therapies In Clinical Trials

02-2729-4219

+886-2-2729-4219

License/价格

OX40标靶治疗药的临床试验，治疗方法，专利技术平台，市场机会(2026年)

OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

目录

第1章 OX40/OX40L途径的简介

第2章以OX40/OX40L途径作为标的治疗

第3章 OX40/OX40L标靶治疗的适应

第4章 OX40/OX40L标的联合治疗

第5章 OX40/OX40L标靶治疗的全球的临床试验概要

第6章有关OX40/OX40L标靶治疗的临床试验的全球的洞察(企业，国家，适应症，各相)

第7章 OX40/OX40L标靶治疗开发平台(各企业)

第8章全球OX40/OX40L标靶治疗市场展望

第9章全球OX40/OX40L标靶治疗市场动态

第10章竞争情形